
Receive Windhover's unique market insight fast with our free alert
service 'Windhover's Update', including the latest abstracts
and summaries from:
IN VIVO
Start-Up
The RPM Report
Medtech Insight
Sign up
now
|
|

|
InterContinental Mark Hopkins • San Francisco
Register before September 30th, 2010 and save!
Taking the Risk out of Asia: Top Pharma Leaders Share Best Practices
Benchmark your Asia strategies against the best and the brightest. 2010
PharmAsia speakers include:
|
Featured speakers include: |
 |
 |
 |
 |
Takeda's Investment Expansion Strategy in Asia
|
Biogen Idec's Strategy in Asia |
Big Pharma Perspective: Comparing Emerging Markets
Strategies
|
Pre-Competitive Collaboration in Asia - A New Model for Sharing Risks, Reaping Rewards |
Graeme R Martin PhD
President & CEO
Takeda Research Investment
|
Gunther Winkler PhD
Senior VP Asia Pacific and Global Government
Strategy
Biogen Idec
|
Ramesh Subrahmanian
Senior VP & President of Asia Pacific Human
Health
Merck & Co.
|
Neil W. Gibson PhD
Chief Scientific Officer, Oncology Research
Pfizer |
 |
 |
 |
 |
|
Catch Up on Asian Market Trends and Data |
The Asia Strategy for a Biotech Company:
What is the Right Kind of Deal?
|
Beyond Cost Arbitrage and More Shots on Goal: India Opportunity for Innovation |
Jan Willem Eleveld
VP Consulting & Services
Asia Pacific
IMS Management Consulting |
Anthony Coles, MD, MPH
CEO
Onyx Pharmaceuticals |
Jan-Anders Karlsson, PhD
CEO
S*Bio (Singapore) |
Rashmi H. Barbhaiya
CEO & Managing Director Advinus Therapeutics (Bangalore, India) |
|
|
Experience Expert Insight From the Leading Asia Thought Leaders: |
|
Li Chen, PhD
Former Head of Research & CSO
Roche R&D Center China
Charles Hsu, PhD, MBA
Partner
Bay City Capital
Jonathan Wang, PhD, MBA
Senior Managing Director, Asia
OrbiMed Advisors
Yi Chengdong
Deputy Director General
Shanghai FDA
John Celebi
VP, Business Development, New Products & Alliance Management
ArQule Inc.
George G. Montgomery
Managing Director
Montgomery Marshall Healthcare Partners
Sanjiv Navangul, MBA, MSD
Director - Chronic Care, Specialty, Care Disease Management India
Merck & Co., Inc. (Mumbai, India)
Hongbo Lu, PhD
VP & Senior Research Analyst - China Healthcare
Piper Jaffray
|
Lee Byung-Keun
CEO
Green Cross (Seoul, Korea)
Graeme Martin, PhD
President & CEO
Takeda Research Investment
Utkarsh Palnitkar
Executive Director
Centrum Capital
Bruce Ross
India Office Director
U.S. FDA
Chris Hickey
China Office Director
U.S. FDA
Jim Toole
Senior Director, Oncology New Product Planning
Daiichi Sankyo
Chae Kyuhan
Deputy Director of Pharmaceutical Safety
Korea FDA
Thomas Slater
VP Commercial Development & International
Cubist Pharmaceuticals |
|
For complete agenda and list of speakers, click here
Western firms increasingly look at Asia as a major new market for their existing products and an inexpensive alternative venue for conducting clinical development and manufacturing operations. Representing nearly two-thirds of the world's population, this diverse powerhouse is expected to play a much larger role in coming decades in bringing innovative products to market.
As they get more involved in Asia, biopharma manufacturers are becoming more sophisticated about how they navigate in different countries. For larger companies, the efforts are not new, only they are more intense, with much greater commitment and resources behind them than in the past. The stakes are higher and companies must take a pragmatic, tactical perspective, even as they are drawn to the strategic opportunities. For small companies, engaging in Asia for the first time, with limited resources, means assessing accurately the intricacies of individual countries, as well as the best approaches to working in the region as a whole.
This year's PharmAsia Summit brings Asian, US and European industry leaders to San Francisco to share their experiences and help both those working directly in Asia and those situated in the West but involved in Asian operations or planning Asia strategy to better understand the myriad of complex challenges and equally attractive opportunities facing them.
BEYOND THE BASICS! PharmAsia Summit is the only event featuring marquee-level speakers and topics by the powerhouse editorial team from
IN VIVO, Start-Up, "The Pink Sheet" and
PharmAsia News.
PharmAsia Summit 2010 delivers the following sessions and more:
-
Catch Up on Asian Market Trends and Data
-
Biotech Perspective Biotech Perspective: Opportunities and Challenges In Asia
- Biogen Idec’s Strategy in Asia
- The Asia Strategy for a Biotech Company: What
is the Right Kind of Deal?
- S*Bio (the largest Singapore Based Biotech)/Onyx
(California) Deal: One of the Largest Biotech Deals in Asia
- Lessons Learned in
Outsourcing: How Much Risk is Too Much?
- Building the Largest Biologics
Contract Mfg Facility in Asia
- Grasping the Ins and Outs of Pricing, Market
Access, IP Challenges in India
- Abbott’s $3.72 B Acquisition of Piramal
Healthcare Solutions: How Abbott is Now the Largest Pharma Presence in India
-
Merck’s Risk Sharing and Genzyme’s Malaria Deal
- Big Pharma Perspective:
Comparing Emerging Markets Strategies: Acquisition vs. Organic growth?
- Betting
on Different Models of Innovation in China: New Paths to New Products
-
Comparing a Large Pharma’s Development Strategies and Capabilities vs. a CRO’s
-
Expanding Roche’s Brick and Mortar Facility in China
- Incubating Innovative
Product Companies Out of China
- Case Studies of New Models for Japanese
Dealmaking
- Partnering with 2 Japanese Pharmas on the Same Compound:
Daiichi-Sankyo and Kyowa Hakko Kirin
- Regulatory Risks: Market Access,
Compulsory Licensing, Approvals and Data Exclusivity
- Hear from The Most
Influential Regional FDA in China
- Investment Outlook For Asia: What Bets
should you Make?
- Hear from One of the Top VCs in China on Its Many Investments
- Takeda’s Investment Expansion Strategy in Asia
- Commercializing your Drug in
Asia: Case Studies on Marketing Authorization, Pricing, and Market Access
-
Commercializing Januvia: Case Study in India
- Pre-Competitive Collaboration in
Asia – A New Model for Sharing Risks, Reaping Rewards
- China Healthcare Reform:
Who Will Benefit The Most?
- Working with Big Pharma to Help them Navigate the
China Healthcare System
- Who will be the Winners and Losers from China’s Big
Healthcare Reform
PLUS MUCH MORE!
Featuring THE Most Senior Level Business Development, R & D and Regulatory
Strategists in the Industry
Hear all this in the U.S. – you don’t have to
blow your travel budget flying to China and India. Asia leaders are coming here!
PharmAsia Summit is THE most strategic-level meeting where senior
biotech and pharma executives share real-life case studies on how they’re
building a presence in Asia – from drug development to market. PharmAsia
Summit will gather the industry’s most senior leaders to share best
practice case studies, successful business models and strategic partnerships
from discovery to clinical trials.
Join us for two days of interactive discussions, case studies and panels, and capitalize on Asia’s booming pharmaceutical market. |
 |
Here’s just a sample of companies that sent their teams in 2009!
Adjuvant Global Advisors, LLC
Association of Biotechnology Led Enterprises (ABLE)
3S Bio, Inc.
BayBio
BayHelix
Bio Foresight
BioMarin Pharmaceutical
BioPharma Today
Burrill & Company
Chinese-American BioPharmaceutical Society (CABS)
Charles River Laboratories
ChemPartner
California Healthcare Institute
Chinese Pharmaceutical Association
Crown Bioscience
CurrentPartnering
Daylight Forensic & Advisory
Dr. Reddy's Laboratories
DSM Pharmaceutical Products
Eli Lilly Global R&D, China
Eli Lilly and Company
Elsevier Business Intelligence
EuroPharma Today
US Food & Drug Administration (FDA)
FDA CHINA
Genentech
Genomic Health Inc.
Glaxosmithkline
Greenleaf Health Llc
Hutchison Medipharma Ltd.
IN VIVO
Johnson & Johnson
Jubilant Biosys
Jubilant Organosys
Limited |
LEAD Therapeutics
Licensing Executives Society
Lilly Singapore Centre for Drug Discover
Merck & Co. Inc.
Merck Research Laboratories
Nishith Desai Associates
OrbiMed Advisors
Parexel
PharmAsia News
PharmaConnections
Pharmalicensing.com
Pfizer
Pfizer China
Piramal Life Sciences
Procter & Gamble Pharmaceuticals
Quintiles
Roche
Roche R & D Center
Sanofi-Aventis
Simcere Pharmaceutical Group
Sino-American Biomedical and Pharmaceutical Association
START-UP
Susquehanna Financial Group
Takeda Pharm Am
Takeda Pharmaceuticals
The Gold Sheet
The Pink Sheet
The Pink Sheet Daily
Transcept Pharmaceuticals
India Chamber of Commerce-USAIC
Veeda
Vertex Pharmaceuticals
Wu Xi Apptec |
Sponsorship Opportunities Available –Access the Most Senior-Level
Decision-Makers at PharmAsia Summit
Why Attend PharmAsia Summit?
- Capitalize on potential new business and collaboration opportunities with the
hottest Asian partners
- Network with hundreds of potential pharmaceutical and biotech partners through
1:1 meetings, cocktail parties, luncheons and refreshment breaks
- Hear about exciting new trends in Asian life sciences and dealmaking strategies
- Meet new partners and clients looking to expand capabilities in Asia
- Benchmark your Asia strategy against what your competitors are doing and why
- Maximize your strategic alliance opportunities by hearing CEOs, senior R&D and
senior business development executives who share lessons learned, practical
advice and strategies on how to build your R&D pipeline - both internally and
externally
- Find out how to commercialize your product, valuate your alliances and develop a
reimbursement strategy in Asia
- Hear expert panels about drug development in Asia — viewpoints from the top
investigators in the field
- Hear only from handpicked sessions, by FDC/Windhover’s #1 editorial department (PharmAsia
News, ”The Pink Sheet,” IN VIVO and Start-Up)
- Hone your dealmaking skills at our compelling plenary & keynote sessions from
industry thought leaders on new trends and dealmaking strategies
- Find key new financing sources to fuel your growth
- Showcase your company’s products and services in front of the most active
dealmakers — who are actively seeking you
Why sponsor PharmAsia Summit?
Windhover and PharmAsia News are making available a limited number of
sponsorships in conjunction with this event, ensuring great visibility among a
select number of companies. Here are just some of the reasons you should
consider a PharmAsia Summit Sponsorship:
- China, India and emerging markets in Asia are the
hottest regions for R&D and commercial growth for big pharma. PharmAsia
Summit will attract senior-level executives in R&D, government & legal
affairs, and business development & licensing from major pharmaceutical and
biotechnology companies growing their business in this region. Associating your
firm as a sponsor of the event ensures that key decision-makers recognize your
brand as a leader in the region.
- PharmAsia Summit will attract some of the
most notable names in the industry to speak candidly of the opportunities and
challenges in China, India and emerging markets for biopharma. This assures that
your brand is associated with an informative event that delivers real value to
its attendees.
- PharmAsia Summit will attract senior executives from throughout the biotech and
pharmaceutical industries, creating a rich dynamic of key decision-makers
comparing notes on strategic issues that will impact everyone in the room. As a
sponsor to this event, you will be regarded as a co-host to our intellectual
gathering, reaping the benefits of high visibility and recognition as an
industry thought leader
Sponsoring PharmAsia Summit provides unparalleled access to key
decision-makers and today’s leading executives. Connect your organization to the
most respected and knowledgeable health care information provider by sponsoring.
Learn more.
|
|
Sponsors |
|
- Global Sponsors -

-
Gold Sponsors -

 |
-
Silver Sponsor -
 |
-
Regional Partners & Supporting Organizations -
-
Association Sponsors
-
- Major Supporting Publications -
- Media Partners -
|
|
|
 |
|
|
|
|
| |
 |
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Novartis is mirroring its approach to pharma R&D and leveraging the byproducts of its biomarker work there to build a commercial molecular diagnostics franchise. The head of the unit talks about its structure, strategy and programs. . . [MORE] (IN VIVO)
Bioactive Technologies For Bone Replacement
Expanded indications for bone morphogenetic proteins and new alternatives to those first-generation bone growth factors have the potential to grow the $2 billion market for bone replacement materials. . . [MORE] (Start-Up)
Laser Cataract Surgery Comes into Focus at ASCRS
The mood was primarily upbeat at April's annual meeting of the American Society of Cataract and Refractive Surgery. Most in attendance expected a modest rebound in procedure volumes for 2010. . . [MORE] (Medtech Insight)
FDA, Drug Development and Health Care Reform: A Panel Discussion
Current and former FDA officials and a former Big Pharma head of R&D discuss FDA and the relationship between a regulator and the industry it regulates when it comes to drug development. . . [MORE] (The RPM Report)
Read
more from the latest:
IN VIVO,
Start-Up,
The RPM Report,
Medtech Insight, "The Pink Sheet",
"The Pink Sheet" DAILY,
"The Rose Sheet",
"The Tan Sheet",
PharmAsia News,
Pharmaceutical Approvals Monthly, and
"The Gray Sheet".
|
|
|
|
| |
|
|
|
|
|